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Several loci and genes are associated with Parkinson’s disease (IPD) with some interacting at
a cellular level. For example PINK1 activates Parkin through phosphorylation of ubiquitin and
enhances Parkin-mediated elimination of damaged mitochondria (mitophagy). Mutations in both
may result in deregulation of mitochondrial homeostasis leading to neurodegeneration (Olszewska
et al., 2014). Intimate knowledge of the interplay between gene products will be crucial for
targeted-therapeutic development and pathway-based treatment initiatives (e.g., Parkin activators
to enhance its housekeeping abilities in PD; Kazlauskaite et al., 2014).
Dhungel et al. (2015) reported an unexpected interaction between two rare IPD genes: VPS35
(Vacuolar sorting protein 35) and EIF4G1 (Eukaryotic translation initiation factor 4 gamma 1). It is
important to understand the role ofVPS35 and EIF4G1 first to fully appreciate complex interactions
between them.
VPS35 is a subunit of the retromer complex first described in yeast in 1998 (Small and Petsko,
2015). The retromer is crucial in mediating retrograde transport of specific membrane proteins
(cargo; Seaman, 2012) from endosomes back to the trans-Golgi network (hydrolases and proteases)
and to the cell surface (Small and Petsko, 2015). In yeast the retromer consists of 5 proteins
encoded by vacuole sorting proteins (VPS) genes: the cargo recognition trimer (VPS 26, 29, and
35) and trimer recruitment dimer (VPS 5 and 17). Eukaryote proteins corresponding to VPS5 and
VPS17 are members of the sorting nexin (Snx) family called Snx-BAR proteins (Seaman, 2012) and
mediate tubule or vesicle formation into which cargo is assigned for different cellular destinations.
The retromer has an important role in secretion of signaling proteins (Wnt) and apoptotic cell
clearance. Absence of retromer activity causes decreasedWnt secretion and dopaminergic neuronal
loss (Seaman, 2012). Moreover the retromer transports VPS10, an important receptor family, is
linked to Alzheimer’s disease and frontotemporal dementia (Lane et al., 2012).
VPS35 is a central scaffold for binding of other subunits of the retromer. Decreased levels
of VPS35 and VPS26 were shown in brain regions susceptible to Alzheimer’s disease in mice
(Muhammad et al., 2008). Mutations in VPS35 (p.Asp620Asn) are associated with familial and
rarely sporadic young-onset levodopa-responsive IPD without dementia providing evidence of the
retromer involvement in neurodegeneration (Bonifati, 2014). The mutation frequency is reported
at 1% in Caucasians and Japanese (Sudhaman et al., 2013).
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EIF4G1 encodes a protein which has a role in protein
regulation. EIF4G1 is part of a multi-subunit translation
initiation complex regulating recruitment of mRNA to the
ribosome. The pathogenicity of EIF4G1 mutations is debated. A
R1205H variant (Chartier-Harlin et al., 2011) was reported in a
family with 10 affected members and mild course of levodopa-
responsive disease and one sporadic Irish patient (McCarthy,
2014). A502V variant was also found in two other PD patients.
The R12O5H co-segregated with the disease and both R1205H,
A502V mutations were absent in controls. In addition the
binding within the translation initiation complex and formation
of the larger complex were impaired indicating loss-of-function
in keeping with a neurodegenerative disorder and was supportive
of the pathogenicity of EIF4G1mutations (Chartier-Harlin et al.,
2011).
Subsequently evidence has suggested that R1205H is only
a benign polymorphism (Dhungel et al., 2015) as a number
of studies identified R1205H in both patients and controls
(Nuytemans et al., 2013; Dhungel et al., 2015; Nichols et al., 2015).
The majority of South African and Asian studies (Quadri et al.,
2013; Nishioka et al., 2014; Weng et al., 2015) failed to identify
EIF4G1 mutations either in patients or in controls (Sudhaman
et al., 2013). In Caucasians themutations occur in 11.57% familial
cases and 0.09% sporadic cases (Sudhaman et al., 2013).
The largest study (2146 sporadic and familial patients)
examining the pathogenicity of EIF4G1 mutations was reported
in 2014 in Iceland (Huttenlocher et al., 2015). The R1205H
was found in one sporadic PD patient and in 76 of 93,698
Icelanders over age 65 (five later found to have IPD symptoms).
It was shown that EIF4G1 is not a high-risk IPD locus and
R1205H was not significantly associated with an increased IPD
risk (Huttenlocher et al., 2015). The most recent meta-analysis
demonstrated EIF4G1 to be an extremely rare cause of IPD with
the mutation frequency 0.23% for R1205H and 0.04% for A502V
(Deng et al., 2015).
As both VPS35 and EIF4G1 are involved in protein signaling
pathways, and interactions between them have been examined
in multiple yeast and transgenic mice models in search for
therapeutic options.
EIF4G1 has two equivalents in yeast: TIF4631 and TIF4632.
Dhungel at al. focused on the TIF4631 deletion which is closly
related to humans and leads to global alteration in translation
rate, unlike the TIF4632 deletion (Dhungel et al., 2015).
By the use of a Synthetic Genetic Array (SGA) 144 synthetic
sick or lethal genes for TIF46311 (EIF4G1 homolog) and 59
for VPS 351 were obtained (Dhungel et al., 2015). GO-Term-
Finder was used to detect any important gene interactions. 14
lethal interactions were found to be common for both genes.
A yeast ortholog of ARFGAP1 encoding a GTPase –activating
protein was common to both screens and has known interactions
with, another IPD related gene, LRRK2. One of the strongest
results from the TIF46311 screen was the equivalent of human
Synaptojanin 1, recently connected to the early IPD (Quadri et al.,
2013). The SGA is an efficient method which could potentially be
used in the prediction of novel IPD genes.
Dhungel et al. did not find any lethal interaction between
the yeast EIF4G1 homolog and VPS351 (Dhungel et al., 2015).
Upregulation of TIF4631, (in contrast to all other four yeast
translation initiation factors) in VPS351 cells was highly toxic;
however this effect was not seen in wild-type yeast cells.
These results were replicated in human cells where EIF4G1
upregulation caused translation-defects and accumulation of
mis-folded proteins. While co-expression of VPS35 was able to
save the cells from toxicity, the expression of VPS35 IPD-linked
mutation (D620N) failed to provide protection (Dhungel et al.,
2015).
Upregulation of EIF4G1 (yeast TIF4631) was toxic in
cells lacking VPS10. VPS10 acts downstream to VPS35 and
overexpression of VPS10 supresses the toxicity related to TIF4631
upregulation in VPS351 (Dhungel et al., 2015).
The authors examined the relation of both genes to alpha-
synuclein accumulation by analyzing transgenic mice where
upregulation of wild type VPS35 rescued alpha-synuclein
induced neurodegeneration, unlike upregulation of VPS35 IPD-
linkedmutants (P316S andD620N) when increased hippocampal
neuronal cell loss was found (Dhungel et al., 2015).
Dhungel et al. showed that the expression ofVPS35 suppresses
alpha-synuclein accumulation and toxicity caused by EIF4G1
upregulation. These proteins work in conjunction and the
retromer and its components may be an important target for a
drug discovery. Modulation of retromer function by increasing
the level of VPS35 could enhance intracellular transport. It
was shown in pre-clinical studies that the enhancement of the
retromer function reverses the neurotoxic effects without any
obvious toxicity, however further studies are needed (Weng et al.,
2015).
This study has suggested new therapeutic approaches in
IPD involving modulation of VPS35, EIF4G, and retromer
interactions. Although we are closer to understanding the
molecular pathways underlying IPD, these results should be
interpreted with caution in view of an on-going debate
questioning EIF4G1 pathogenicity and further studies to resolve
this dilemma are needed.
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